VB 201

CAS No. 630112-41-3

VB 201( —— )

Catalog No. M34467 CAS No. 630112-41-3

VB 201 is an oxidized phospholipid small molecule with anti-inflammatory activity that inhibits CD14 and Toll-like receptor 2-dependent innate cell activation and limits atherosclerosis, and can be used to study atherosclerosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 296 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    VB 201
  • Note
    Research use only, not for human use.
  • Brief Description
    VB 201 is an oxidized phospholipid small molecule with anti-inflammatory activity that inhibits CD14 and Toll-like receptor 2-dependent innate cell activation and limits atherosclerosis, and can be used to study atherosclerosis.
  • Description
    VB 201 is an oxidized phospholipid small molecule with anti-inflammatory activity that inhibits CD14 and Toll-like receptor 2-dependent innate cell activation and limits atherosclerosis, and can be used to study atherosclerosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    TLR
  • Recptor
    TLR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    630112-41-3
  • Formula Weight
    581.76
  • Molecular Formula
    C29H60NO8P
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [C@H](COP(OCC[N+](C)(C)C)(=O)[O-])(COCCCCCCCCCCCCCCCC)OCCCCC(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • TLR7 agonist 3

    TLR7 agonist 3 is a Toll-like receptor 7 (TLR7) agonist that has anticancer activity and is used in the study of diseases of the immune system.

  • IAXO-102

    IAXO-102 is a TLR4 antagonist that negatively regulates TLR4 signaling.

  • CPG-52364

    CPG-52364 (CPG52364) is an orally available, small molecule TLR7/8/9 antagonist for the treatment of systemic lupus erythematosus and other autoimmune disorders.